Is Retatrutide Approved by Any Regulator?
Short answer: No. As of this writing Retatrutide has not been approved by the FDA, the EMA, the UAE Ministry of Health or any other regulator. It is an investigational compound: its developer, Eli Lilly, completed a phase 2 obesity trial published in 2023 and is running phase 3 trials under the TRIUMPH programme. It is not available as a medicine anywhere.
Investigational means the compound is being studied under trial protocols and has no marketing authorisation. Any product sold as Retatrutide outside a trial is therefore not a medicine, and REVIVE LAB UAE lists it as a research material only.
Approval, if it comes, would follow the phase 3 results and a regulatory review. This page will be updated when the status changes; until then the answer is simply that it is not approved.
REVIVE LAB UAE supplies the pack for laboratory research use only. It is not for human or veterinary use, and no dosing, administration or protocol guidance is provided.
Retatrutide Pack 20 mg — REVIVE LAB UAE
AED 1010 · Lot-specific COA on request · Cash on delivery or USDT (5% off) Order Retatrutide Pack UAE — Live Stock & Pricing
AED 1010 · Lot-specific COA on request · Cash on delivery or USDT (5% off) Order Retatrutide Pack UAE — Live Stock & Pricing
Research-Use Only Disclaimer: This page is published for laboratory and scientific research information purposes only. Nothing here constitutes medical advice, dosing guidance, or a therapeutic recommendation. Products supplied by REVIVE LAB UAE (revivelab.ae) — where applicable — are sold strictly as reference materials for research use, not for human or veterinary consumption. Buyers and readers are solely responsible for compliance with applicable UAE laws and institutional research ethics requirements.